ES2038170T3 - Procedimiento para preparar derivados de quinazolina utiles como agentes anti-tumorales. - Google Patents
Procedimiento para preparar derivados de quinazolina utiles como agentes anti-tumorales.Info
- Publication number
- ES2038170T3 ES2038170T3 ES198787302525T ES87302525T ES2038170T3 ES 2038170 T3 ES2038170 T3 ES 2038170T3 ES 198787302525 T ES198787302525 T ES 198787302525T ES 87302525 T ES87302525 T ES 87302525T ES 2038170 T3 ES2038170 T3 ES 2038170T3
- Authority
- ES
- Spain
- Prior art keywords
- procedure
- tumor agents
- quinazoline derivatives
- preparing useful
- alcoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical group CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- RRBYUSWBLVXTQN-UHFFFAOYSA-N tricyclene Chemical compound C12CC3CC2C1(C)C3(C)C RRBYUSWBLVXTQN-UHFFFAOYSA-N 0.000 abstract 1
- RRBYUSWBLVXTQN-VZCHMASFSA-N tricyclene Natural products C([C@@H]12)C3C[C@H]1C2(C)C3(C)C RRBYUSWBLVXTQN-VZCHMASFSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
UNA QUINAZOLINA DE LA FORMULA (I) DONDE R1 ES ALQUILO, CICLOALQUILO, ALQUENILO,ALQUINILO,ALCOXI, ALQUILTIO, ARILO, ARILOXI, ARILALQUILO, HALOGENO, HIDROXI, MERCAPTO, PIRIDILTIO, PIRIMINIDILTIO; O ALQUILO O ALCOXI SUSTITUIDO DONDE AR ES FENILENO, NAFTILENO O HETEROCICLENO QUE ES NO SUSTITUIDO O SOPORTA UNO O MAS SUSTITUYENTES Y DONDE R3 ES TAL QUE R3-NH2 ES UN AMINOACIDO; O UNA SAL FARMACEUTICAMENTE ACEPTABLE O ESTER DE ELLA. LOS COMPUESTOS POSEEN ACTIVIDAD ANTITUMORAL.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB868607683A GB8607683D0 (en) | 1986-03-27 | 1986-03-27 | Anti-tumor agents |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2038170T3 true ES2038170T3 (es) | 1993-07-16 |
Family
ID=10595358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES198787302525T Expired - Lifetime ES2038170T3 (es) | 1986-03-27 | 1987-03-24 | Procedimiento para preparar derivados de quinazolina utiles como agentes anti-tumorales. |
Country Status (22)
Country | Link |
---|---|
US (2) | US4992550A (es) |
EP (1) | EP0239362B1 (es) |
JP (1) | JPH0657699B2 (es) |
AR (1) | AR244213A1 (es) |
AT (1) | ATE70057T1 (es) |
AU (1) | AU592628B2 (es) |
CA (1) | CA1285943C (es) |
DE (1) | DE3774909D1 (es) |
DK (1) | DK166621B1 (es) |
ES (1) | ES2038170T3 (es) |
FI (1) | FI89912C (es) |
GB (2) | GB8607683D0 (es) |
GR (1) | GR3003282T3 (es) |
HK (1) | HK8594A (es) |
HU (1) | HU197317B (es) |
IE (1) | IE60302B1 (es) |
IL (1) | IL81924A (es) |
LU (1) | LU88797I2 (es) |
NL (1) | NL970024I2 (es) |
NO (2) | NO173545C (es) |
PT (1) | PT84571B (es) |
ZA (1) | ZA871998B (es) |
Families Citing this family (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8513754D0 (en) * | 1985-05-31 | 1985-07-03 | Jones T R | Anti-cancer quinazoline derivatives |
GB8625019D0 (en) * | 1986-10-18 | 1986-11-19 | Wellcome Found | Compounds |
GB8707053D0 (en) * | 1987-03-25 | 1987-04-29 | Ici Plc | Anti-tumour agents |
US4857530A (en) * | 1987-11-03 | 1989-08-15 | Warner-Lambert Company | Substituted quinazolinones as anticancer agents |
GB8727737D0 (en) * | 1987-11-26 | 1987-12-31 | Ici Plc | Antitumour agents |
US4940713A (en) * | 1988-04-15 | 1990-07-10 | Burroughs Wellcome Co. | Substituted glutamic acids |
US5019577A (en) * | 1988-04-15 | 1991-05-28 | Burroughs Welcome Co. | Novel compounds and use |
GB8809978D0 (en) * | 1988-04-27 | 1988-06-02 | Ici Plc | Anti-tumour agents |
EP0365763A1 (en) * | 1988-09-30 | 1990-05-02 | Agouron Pharmaceuticals, Inc. | Antiproliferative cyclic compounds |
GB8829296D0 (en) * | 1988-12-15 | 1989-01-25 | Ici Plc | Anti-tumour compounds |
US5252573A (en) * | 1988-12-15 | 1993-10-12 | Imperial Chemical Industries Plc | Anti-tumor agents |
US5286726A (en) * | 1990-04-12 | 1994-02-15 | The Regents Of The University Of Michigan | Difluoroglutamic acid conjugates with folates and anti-folates for the treatment of neoplastic diseases |
IL98167A0 (en) * | 1990-05-30 | 1992-06-21 | Ici Plc | Anti-tumour quinazoline derivatives,processes for their preparation and pharmaceutical compositions comprising them |
GB9013615D0 (en) * | 1990-06-19 | 1990-08-08 | Wellcome Found | Pharmaceutical compounds |
US5290780A (en) * | 1991-01-30 | 1994-03-01 | American Cyanamid Co. | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
GB9105771D0 (en) * | 1991-03-19 | 1991-05-01 | Cancer Res Inst Royal | Anti-cancer compounds |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
ATE147386T1 (de) * | 1991-08-12 | 1997-01-15 | Takeda Chemical Industries Ltd | Kondensierte pyrimidinderivate, ihre herstellung und ihre verwendung als antitumormittel |
US5145854A (en) * | 1991-11-27 | 1992-09-08 | Nair Madhavan G | 1-formyl-5,8,10-trideazafolates |
GB9205320D0 (en) * | 1992-03-11 | 1992-04-22 | Ici Plc | Anti-tumour compounds |
GB9205907D0 (en) * | 1992-03-18 | 1992-04-29 | Cancer Res Inst Royal | Anti-cancer compounds |
ES2049659B1 (es) * | 1992-10-08 | 1994-10-16 | Ici Plc | Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena. |
GB9223352D0 (en) * | 1992-11-06 | 1992-12-23 | Ici Plc | Tricyclic compounds |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
US7910624B1 (en) | 1995-03-03 | 2011-03-22 | The Trustees Of Boston University | Compositions for the treatment of blood disorders |
CA2174737C (en) * | 1993-10-29 | 2008-04-22 | Douglas V. Faller | Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents |
US6011000A (en) * | 1995-03-03 | 2000-01-04 | Perrine; Susan P. | Compositions for the treatment of blood disorders |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
US5593999A (en) * | 1995-06-07 | 1997-01-14 | Nair; Madhavan G. | Non-classical folate analogue inhibitors of glycinamide ribonucleotide formyltransferase (GARFT) |
US6420427B1 (en) * | 1997-10-09 | 2002-07-16 | Ono Pharmaceutical Co., Ltd. | Aminobutyric acid derivatives |
US5912251A (en) * | 1998-01-17 | 1999-06-15 | Nair; Madhavan G. | Metabolically inert anti-inflammatory and anti-tumor antifolates |
WO1999040883A2 (en) * | 1998-02-11 | 1999-08-19 | Faller Douglas V | Compositions and methods for the treatment of cystic fibrosis |
GB9904275D0 (en) | 1999-02-24 | 1999-04-21 | Cancer Res Campaign Tech | Anti-cancer compounds |
US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
US7671200B2 (en) * | 1999-10-27 | 2010-03-02 | Cytokinetics, Inc. | Quinazolinone KSP inhibitors |
US7230000B1 (en) * | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
US6143776A (en) * | 2000-02-02 | 2000-11-07 | Sunesis Pharmaceuticals, Inc. | Tosylproline analogs as thymidylate synthase inhibitors |
US6995171B2 (en) | 2001-06-21 | 2006-02-07 | Agouron Pharmaceuticals, Inc. | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents |
ATE526028T1 (de) | 2001-08-31 | 2011-10-15 | Btg Int Ltd | Verwendung von cyclopentaägüchinazoline-derivaten zur krebsbehandlung |
EP2332962A1 (en) | 2001-08-31 | 2011-06-15 | BTG International Limited | Cyclopenta[g]quinazoline compounds for use in the treatment of inflammatory or allergic conditions |
AU2002346471A1 (en) * | 2001-11-20 | 2003-06-10 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
AU2003213092A1 (en) * | 2002-02-15 | 2003-09-09 | Smithkline Beecham Corporation | Syntheses of quinazolinones |
PT2275102E (pt) | 2002-03-13 | 2015-10-27 | Array Biopharma Inc | Derivados de benzimidazole alquilado n3 como inibidores de mek |
RU2004135554A (ru) * | 2002-05-09 | 2006-01-20 | Цитокинетикс, Инк. (Us) | Пиримидиноны, композиции на их основе и способы их использования |
US7214800B2 (en) * | 2002-05-09 | 2007-05-08 | Cytokinetics, Inc. | Compounds, compositions, and methods |
AU2003265242A1 (en) * | 2002-05-23 | 2003-12-22 | Cytokinetics, Inc. | Compounds, compositions, and methods |
EP1556357A4 (en) * | 2002-06-14 | 2006-09-13 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
WO2004009036A2 (en) * | 2002-07-23 | 2004-01-29 | Cytokinetics, Inc. | Compounds compositions and methods |
JP2005536553A (ja) * | 2002-08-21 | 2005-12-02 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
AU2003277079A1 (en) * | 2002-09-30 | 2004-05-04 | Cytokinetics, Inc. | Compounds, compositions, and methods |
ES2338545T3 (es) | 2002-12-20 | 2010-05-10 | Pfizer Products Inc. | Derivados de pirimidina para el tratamiento del crecimiento celular anormal. |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
WO2005041888A2 (en) * | 2003-11-03 | 2005-05-12 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions and methods |
EP1680420A4 (en) * | 2003-11-07 | 2008-09-24 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
WO2005051301A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
JP2007513154A (ja) * | 2003-12-08 | 2007-05-24 | サイトキネティクス・インコーポレーテッド | 化合物、組成物及び方法 |
WO2005116035A1 (en) | 2004-05-27 | 2005-12-08 | Pfizer Products Inc. | Pyrrolopyrimidine derivatives useful in cancer treatment |
JP2008512490A (ja) | 2004-09-08 | 2008-04-24 | チェルシー・セラピューティクス,インコーポレイテッド | 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤 |
US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
AP2552A (en) | 2005-04-26 | 2013-01-08 | Pfizer | P-cadherin antibodies |
AR055057A1 (es) | 2005-05-18 | 2007-08-01 | Array Biopharma Inc | Inhibidores heterociclicos de mek, formas cristalinas de los mismos, procesos para su preparacion y metodos de uso de los mismos en composiciones farmaceuticas y medicamentos para el tratamiento de un trastorno hiperproliferativo o de una condicion inflamatoria. |
US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
PL2960253T3 (pl) | 2005-09-07 | 2018-11-30 | Amgen Fremont Inc. | Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1 |
WO2007121269A2 (en) | 2006-04-11 | 2007-10-25 | Ardea Biosciences, Inc. | N-aryl-n'alkyl sulfamides as mek inhibitors |
CN101454004B (zh) | 2006-04-18 | 2013-12-04 | 阿迪亚生命科学公司 | 作为mek抑制剂的吡啶酮磺酰胺类和吡啶酮硫酰胺类 |
WO2007132307A1 (en) | 2006-05-09 | 2007-11-22 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
JP2010516694A (ja) | 2007-01-19 | 2010-05-20 | チェルシー・セラピューティクス,インコーポレイテッド | 新規な伝統的葉酸拮抗剤 |
WO2010105112A1 (en) * | 2009-03-11 | 2010-09-16 | Hemaquest Pharmaceuticals, Inc. | Detection of short-chain fatty acids in biological samples |
WO2010108652A1 (en) | 2009-03-27 | 2010-09-30 | Ardea Biosciences Inc. | Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors |
LT2445502T (lt) * | 2009-06-25 | 2017-09-25 | Alkermes Pharma Ireland Limited | Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui |
US20120157471A1 (en) | 2009-09-01 | 2012-06-21 | Pfizer Inc. | Benzimidazole derivatives |
US20110086869A1 (en) | 2009-09-24 | 2011-04-14 | The Trustees Of Boston University | Methods for treating viral disorders |
WO2011056957A2 (en) | 2009-11-06 | 2011-05-12 | Chelsea Therapeutics, Inc. | Enzyme inhibiting compounds |
WO2011068403A2 (en) | 2009-12-02 | 2011-06-09 | Ultimorphix Technologies B.V. | Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts |
CN102802412A (zh) | 2009-12-08 | 2012-11-28 | 海玛奎斯特医药公司 | 用于治疗红细胞病症的方法及低剂量方案 |
ES2647361T3 (es) * | 2010-01-07 | 2017-12-21 | Alkermes Pharma Ireland Limited | Profármacos de sales de amonio cuaternario |
DK3150610T3 (da) | 2010-02-12 | 2019-11-04 | Pfizer | Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on |
US20110245154A1 (en) | 2010-03-11 | 2011-10-06 | Hemaquest Pharmaceuticals, Inc. | Methods and Compositions for Treating Viral or Virally-Induced Conditions |
AU2011270701B2 (en) | 2010-06-24 | 2015-05-14 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
BR112013005223A2 (pt) | 2010-09-03 | 2016-05-03 | Bayer Ip Gmbh | "pirimidinonas e dihidropirimidinonas fusionadas substituídas." |
WO2012052948A1 (en) | 2010-10-20 | 2012-04-26 | Pfizer Inc. | Pyridine- 2- derivatives as smoothened receptor modulators |
WO2012078708A1 (en) | 2010-12-07 | 2012-06-14 | Chelsea Therapeutics, Inc. | Combination comprising methotrexate and an antifolate compound |
GB201103578D0 (en) | 2011-03-02 | 2011-04-13 | Sabrepharm Ltd | Dipyridinium derivatives |
CA2830511C (en) | 2011-03-18 | 2021-09-14 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising aripiprazole lauroxil and sorbitan laurate |
JP5914667B2 (ja) | 2011-09-22 | 2016-05-11 | ファイザー・インク | ピロロピリミジンおよびプリン誘導体 |
CN102424679B (zh) * | 2011-11-15 | 2014-07-30 | 扬子江药业集团有限公司 | 一种雷替曲塞的制备方法 |
CA2867121C (en) | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
US9999670B2 (en) | 2012-03-19 | 2018-06-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
US9993556B2 (en) | 2012-03-19 | 2018-06-12 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty glycerol esters |
EP3718536A1 (en) | 2012-09-19 | 2020-10-07 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
US20150104392A1 (en) | 2013-10-04 | 2015-04-16 | Aptose Biosciences Inc. | Compositions, biomarkers and their use in the treatment of cancer |
UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
MA39495A (fr) | 2014-03-20 | 2015-09-24 | Alkermes Pharma Ireland Ltd | Formulations d'aripiprazole présentant des vitesses d'injection plus élevées |
WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
BR112016024513A2 (pt) | 2014-04-30 | 2017-08-15 | Pfizer | derivados de di-heterociclo ligados à cicloalquila |
WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
EP3227279B1 (en) * | 2014-12-02 | 2019-02-13 | Eli Lilly and Company | 1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as aicarft inhibitors in the treatment of cancers |
ES2746839T3 (es) | 2014-12-18 | 2020-03-09 | Pfizer | Derivados de pirimidina y triazina y su uso como inhibidores de AXL |
CN104447724B (zh) * | 2014-12-31 | 2017-11-10 | 四川峨嵋山药业有限公司 | 一种雷替曲塞的精制方法 |
CN108289892B (zh) | 2015-06-29 | 2021-11-23 | 维瑞斯特姆股份有限公司 | 治疗组合物、组合和使用方法 |
WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
GB2543550A (en) | 2015-10-21 | 2017-04-26 | Hox Therapeutics Ltd | Peptides |
PL3402503T3 (pl) | 2016-01-13 | 2021-04-19 | Acerta Pharma B.V. | Kombinacje terapeutyczne antyfolianu oraz inhibitora btk |
CN106957311B (zh) * | 2016-12-29 | 2020-03-31 | 南京正大天晴制药有限公司 | 雷替曲塞的溶剂化物及其制备方法 |
CN106957312B (zh) * | 2016-12-29 | 2019-11-01 | 南京正大天晴制药有限公司 | 雷替曲塞水合物晶型及其制备方法 |
EP3761983A1 (en) | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
CN109734698B (zh) * | 2019-01-25 | 2020-07-17 | 宏冠生物药业有限公司 | 一种雷替曲塞关键中间体的合成工艺 |
EP3976198A4 (en) | 2019-05-31 | 2023-07-19 | Viracta Subsidiary, Inc. | METHODS OF TREATMENT OF VIRAL ASSOCIATED CANCER WITH HISTONE DEACETYLASE INHIBITORS |
JP7352662B2 (ja) | 2019-06-18 | 2023-09-28 | ファイザー・インク | ベンゾイソオキサゾールスルホンアミド誘導体 |
AU2020295006B2 (en) | 2019-06-19 | 2023-11-09 | Ctxt Pty Ltd | Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1021196A (en) * | 1964-02-20 | 1966-03-02 | Parke Davis & Co | Novel amino acids and means for producing the same |
GB2065653B (en) * | 1979-12-19 | 1983-03-09 | Nat Res Dev | Anti-cancer quinazoline derivatives |
GB8513754D0 (en) * | 1985-05-31 | 1985-07-03 | Jones T R | Anti-cancer quinazoline derivatives |
-
1986
- 1986-03-27 GB GB868607683A patent/GB8607683D0/en active Pending
-
1987
- 1987-03-16 IE IE69987A patent/IE60302B1/en not_active IP Right Cessation
- 1987-03-16 FI FI871139A patent/FI89912C/fi not_active IP Right Cessation
- 1987-03-18 IL IL81924A patent/IL81924A/xx not_active IP Right Cessation
- 1987-03-18 ZA ZA871998A patent/ZA871998B/xx unknown
- 1987-03-20 AU AU70472/87A patent/AU592628B2/en not_active Expired
- 1987-03-24 AT AT87302525T patent/ATE70057T1/de active
- 1987-03-24 GB GB8706948A patent/GB2188319B/en not_active Expired
- 1987-03-24 DE DE8787302525T patent/DE3774909D1/de not_active Expired - Lifetime
- 1987-03-24 LU LU88797C patent/LU88797I2/fr unknown
- 1987-03-24 ES ES198787302525T patent/ES2038170T3/es not_active Expired - Lifetime
- 1987-03-24 EP EP87302525A patent/EP0239362B1/en not_active Expired - Lifetime
- 1987-03-26 PT PT84571A patent/PT84571B/pt unknown
- 1987-03-26 CA CA000533035A patent/CA1285943C/en not_active Expired - Lifetime
- 1987-03-26 NO NO871266A patent/NO173545C/no unknown
- 1987-03-26 DK DK155087A patent/DK166621B1/da not_active IP Right Cessation
- 1987-03-27 HU HU871343A patent/HU197317B/hu unknown
- 1987-03-27 JP JP62071960A patent/JPH0657699B2/ja not_active Expired - Lifetime
- 1987-03-27 AR AR87307137A patent/AR244213A1/es active
-
1989
- 1989-04-06 US US07/334,748 patent/US4992550A/en not_active Expired - Lifetime
-
1990
- 1990-09-05 US US07/577,579 patent/US5081124A/en not_active Expired - Lifetime
-
1991
- 1991-12-05 GR GR91401138T patent/GR3003282T3/el unknown
-
1994
- 1994-01-21 HK HK85/94A patent/HK8594A/xx not_active IP Right Cessation
-
1997
- 1997-07-07 NL NL970024C patent/NL970024I2/nl unknown
-
1998
- 1998-09-08 NO NO1998020C patent/NO1998020I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2038170T3 (es) | Procedimiento para preparar derivados de quinazolina utiles como agentes anti-tumorales. | |
ES530263A0 (es) | Procedimiento para la obtencion de derivados de guanidina | |
ES2021266B3 (es) | Nuevos derivados de quinazolina, procedimiento para su produccion y composiciones farmaceuticas que los contienen. | |
FI873467A0 (fi) | Menetelmä 5-amino-4-hydroksivaleriaanahappojohdannaisten valmistamiseksi | |
MX162950B (es) | Procedimiento para preparar derivados de acidos piridoncarboxilicos | |
ES2044982T3 (es) | Un procedimiento para preparar un compuesto que inhibe las enzimas lipoxigenasas. | |
ES529811A0 (es) | Procedimiento para preparar derivados de n-fenil-benzamida | |
ES538418A0 (es) | Un derivado de indol-3-carboxamida | |
AR241531A1 (es) | Un procedimiento para la preparacion derivados de 2-indolinona, y sus sales farmaceuticamente aceptables. | |
DK519985A (da) | Quinoloncarboxylsyrederivater, fremgangsmaade til fremstilling deraf og antibakterielt middel indeholdende saadanne derivater | |
NO167746C (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktive muramylpeptidderivater. | |
FI863565A0 (fi) | Foerfarande foer framstaellning av nya pyrrobenzimidazoler, pyrrolbenzoxazoler och pyrrolbenztiazoler. | |
DK311380A (da) | Triazolyl-alken-derivater fremgangsmaade til fremstilling deraf samt deres anvendelse som fungicider | |
ES2158290T3 (es) | Derivados de tiazolidinona opticamente activos. | |
DK603688A (da) | Middel til behandling af blodhoejtryk og hjerteinsufficiens | |
DK413188D0 (da) | Benzimidazol-derivater til terapeutisk anvendelse og fremgangsmaade til fremstilling deraf | |
ES2038218T3 (es) | Un procedimiento para preparar nuevos derivados de 2-alquilsulfinil-4(3h)-quinazolinona. | |
ES508415A0 (es) | Un procedimiento para preparar nuevos derivados de 1,4-benzotiazina. | |
SE8802814L (sv) | Beredningar foer lokal anvaendning | |
FI872997A (fi) | Amidderivat. | |
ES550944A0 (es) | Un procedimiento para preparar nuevas 1,2,4-tiadiazinas | |
ES552281A0 (es) | Un procedimiento para la preparacion de derivados de homocisteina-tiolactona | |
ES2041755T3 (es) | Procedimiento para la preparacion de nuevas tiadiacinas, e insecticidas. | |
DK119886A (da) | Hidtil ukendte carbacykliner, fremgangsmaade til deres fremstillingog deres anvendelse som laegemiddel | |
PT84160B (pt) | Processo para a preparacao de derivados de 1-acilaminometil-imidazo {1,2-a} quinolainas e de composicoes farmaceuticas que os contem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 239362 Country of ref document: ES |